Compare ELMD & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | PALI |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 359.0M |
| IPO Year | 2010 | 2019 |
| Metric | ELMD | PALI |
|---|---|---|
| Price | $28.50 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $48.50 | $10.22 |
| AVG Volume (30 Days) | 79.5K | ★ 3.2M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.94 | ★ 97.06 |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $54,716,000.00 | $260,000.00 |
| Revenue This Year | $12.71 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | $21.76 | ★ N/A |
| Revenue Growth | 13.83 | ★ 1500.39 |
| 52 Week Low | $23.01 | $1.42 |
| 52 Week High | $47.40 | $2.86 |
| Indicator | ELMD | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 30.46 |
| Support Level | $27.14 | N/A |
| Resistance Level | $28.35 | $2.19 |
| Average True Range (ATR) | 0.84 | 0.12 |
| MACD | 0.65 | -0.04 |
| Stochastic Oscillator | 86.79 | 8.99 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.